Engineered peptides with enzymatically cleavable domains for controlling the release of model protein drug from "soft" nanoparticles

Acta Biomaterialia

Volumn 8, Issue 2, 2012, Pages 636-645

  Singh, Harsh Deep ^a   Bushnak, Ibraheem ^a,b,c   Unsworth, Larry D ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

BSA; Coacervation; Controlled release strategy; Engineered peptide; MMP 2

Indexed keywords

AMINO ACIDS; BODY FLUIDS; MOLECULES; NANOPARTICLES; PEPTIDES; PROTECTIVE COATINGS; TARGETED DRUG DELIVERY; TISSUE;

ALBUMIN NANOPARTICLES; BOVINE SERUM ALBUMINS; CLEAVAGE RATES; COACERVATION; CONTROLED RELEASE STRATEGY; CONTROLLED RELEASE; ENGINEERED PEPTIDE; LOCAL DELIVERY; MATRIX METALLOPROTEINASE-2; RELEASE STRATEGIES;

CONTROLLED DRUG DELIVERY;

BOVINE SERUM ALBUMIN; GELATINASE A; NANOPARTICLE;

ARTICLE; COACERVATION; CONTROLLED DRUG RELEASE; DRUG COATING; DRUG DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN IMMOBILIZATION; PROTEIN STABILITY; STATIC ELECTRICITY;

BOVINAE;

EID: 84855449010     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2011.10.028     Document Type: Article

References (18)

1. M. Rahimnejad, M. Jahanshahi, and G.D. Najafpour Production of biological nanoparticles from bovine serum albumin for drug delivery Afr J Biotechnol 5 2006 1918 1923 (Pubitemid 44736967)
2. Fredric M. Menger, and Bridget M. Sykes Anatomy of a coacervate Langmuir 14 1998 4131 4137 (Pubitemid 128624876)
3. Guilin Wang, Kevin Siggers, Sufeng Zhang, Hongxing Jiang, Zhenge Xu, Ronald F. Zernicke, et al. Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 2008;25:2896-09.
4. H. Nagase, and F. Woessner Matrix metalloproteinase J Biol Chem 274 1999 21491 21494
5. P.S. Burrage, K.S. Mix, and C.E. Brinckerhoff Matrix metalloproteinase: role in arthritis Front Biosci 11 2006 529 543
6. Q.D. Tang, P.S. Wu, Y.Q. Hou, Z. Huang, Z.J. Zhou, and Z.G. Guo Plasma matrix metalloproteinase-2 and 9 levels are elevated in patients with acute coronary syndrome and coronary chronic total occlusion J Southern Med Univ 29 2009 1004 1007
7. A.K. Chow, J. Cena, and R. Schulz Acute actions and novel targets of matrix metalloproteinase in the heart and vasculature Br J Pharmacol 152 2007 189 205 (Pubitemid 47517601)
8. G. Klein, E. Vellenga, M.W. Fraaije, W.A. Kamps, and E.S.J.M. de Bont The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia Crit Rev Oncol Hemat 50 2004 87 100 (Pubitemid 38638736)
9. A. Kugler Matrix metalloproteinases and their inhibitors Anticancer Res 19 1999 1589 1592 (Pubitemid 29255653)
10. Wendy Song, Lori Holle, Eric Holle, Yanzhang Wei, Thomas Wagner, Xianzhong Yu. A matrixmetalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int J Oncol 2003;22:93-98.
11. Sarah Netzel-Arnett, Qing-Xiang Sang, William G.I. Moore, Marc Navre, Henning Birkedal-Hansen, Harold E, et al. Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin), Biochemistry 1993;32:6427-32. (Pubitemid 23208826)
12. Benjamin E. Turk, Lisa L. Huang, Elizabeth T. Piro, Lewis C. Cantley. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries, Nat Biotechnol 2001;19:661-67. (Pubitemid 32625438)
13. Omid Veiseh, Jonathan W. Gunn, Forrest M. Kievit, Conroy Sun, Chen Fang, Jerry S.H. Lee, et al. Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles, Small 2008;5:256-64.
14. Paula Gould. Tumor protease triggers self assembly: nanoparticles. Nanotoday 2006;1:15.
15. H.D. Singh, G. Wang, H. Uluda, and L.D. Unsworth Poly-L-lysine-coated albumin nanoparticles: stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics Acta Biomater 6 2010 4277 4284
16. K. Langer, M.G. Anhorn, I. Steinhauser, S. Dries, D. Celebi, and N. Schrickel Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation Int J Pharm 347 2008 109 117 (Pubitemid 350180317)
17. K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. Von Briesen, and D. Schubert Optimization of the preparation process for human serum albumin (HSA) nanoparticles Int J Pharm 257 2003 169 180 (Pubitemid 36507043)
18. David L. Nelson, Michael M. Cox, Principles of biochemistry. 4th ed. New York: W.H. Freeman; 2004.